177Lu-RM2 (177Lu-BAY-1017858) is a molecule corresponding to a different than PSMA biological approach for treating prostate cancer. Unfortunately, it does not seem that this molecule is presently supported by a private group, but some research was reactivated in 2020 (Phase I/II).
177Lu-RM2 efficiently targets the BBR2 (Bombesin receptor 2) expressed on CRPC cells in vivo. This molecule is associated to the diagnostic agent 68Ga-Bombesin (68Ga-RM2).
Radiation Type: beta electrons (β–)